Table SIII. Neurological symptoms and cerebral abnormalities

Symptoms/abnormalities	Overall ($n = 96$) *n* (%)	LSECDS patients ($n = 70$) *n* (%)	PFH patients ($n = 16$) *n* (%)	LSECDS/PFH overlap-patients ($n = 10$) *n* (%)
Epilepsy	4 (4.2)	3 (4.3)	0	1 (10.0)
Headache	5 (5.2)	2 (2.9)	1 (6.3)	2 (20.0)
Migraine	3 (3.1)	1 (1.4)	2 (12.5)	0
Areas of gliosis	7 (7.3)	2 (2.9)	2 (12.5)	3 (30.0)
White matter lesions	6 (6.3)	4 (5.7)	1 (6.3)	1 (10.0)
Vascular malformation/abnormality	1 (1)	1 (1.4)	0	0
Abnormal cortical size and folding	1 (1)	0	0	1 (10.0)
Any of the symptoms/abnormalities	27 (28.1)	13 (18.6)	6 (37.5)	8 (80.0)

Magnetic resonance imaging (MRI) and/or computed tomography (CT) was performed in 52 (54.2%) of the 96 patients (44 had MRI, 2 had CT and 6 had both MRI and CT).
LSECDS: localized scleroderma "en coup de sabre"; PFH: progressive facial hemiatrophy.